Meet Proteona at EBDC: Heidelberg, 25-26 Sep. 2019

Meet Proteona at the European Business Development Conference in Heidelberg Brina Blum from Unsplash

Meet Proteona at the European Business Development Conference in Heidelberg, Germany

Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology

Dr Andreas Schmidt, the CEO of Proteona Pte. Ltd., will be presenting at the European Business Development Conference taking place in Heidelberg, Germany, from the 25th to the 26th of September 2019.

Dr Schmidt will speak about how Proteona helps to address the unmet clinical need in immuno-oncology, using single cell proteogenomic analysis that captures tumor heterogeneity and the immune microenvironment. Proteona recently announced its collaborative effort with AI Singapore to develop artificial intelligence-assisted tool to realize the full value of its single cell multi-omics data. Dr Schmidt’s talk will take place on the morning of the 25th of September, Wednesday. He will be available during the event for further discussions.

This annual event features speakers from main pharmaceutical companies, and provides a conductive platform for meeting biotech and pharmaceutical partners in Europe.

Conference details

Schedule a meeting

For media queries, please contact:

Dr Andreas Schmidt

About Proteona

Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.